Business
GSK - segment and product sales reporting changes
GSK - segment and product sales reporting changes.
About this update from Gsk Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9686G\n GlaxoSmithKline PLC\n 01 April 2022\n \n \n \n \n \n \n \n Issued: 1 April 2022, London, U.K.\n \n \n \n \n \n \n \n GSK publishes segment and product \n sales \n reporting changes\n \n \n \n \n \n \n \n \n \n \n \n GlaxoSmithKline plc (\"GSK\") keeps its financial reporting under regular review to ensure that it remains current and in line with both the latest regulatory requirements and developing best practice within the Pharmaceutical industry.\n \n \n \n \n \n \n \n \n Revised reporting segments for Pharmaceuticals and Vaccines\n \n \n GSK announced at the Investor Update on 23 June 2021 that revised reporting segments for new GSK would be presented from the first quarter 2022 results. The new operating segments are reported based on the financial information provided to the Chief Executive Officer and the responsibilities of the GSK Leadership Team (GLT).\n Previously, GSK reported results under four segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. From the first quarter 2022 results GSK will report results under three segments on the following basis:\n \n · \n The Commercial Operations segment includes the results that were previously reported under the Pharmaceuticals segment and the Vaccines segment but now excludes expenditure related to research & development included in the segment below. This change reflects the closer integration and management of the commercial, manufacturing and other operations of the Pharmaceutical and Vaccines portfolio. The Commercial Operations segment continues to include the ViiV Healthcare commercial operating profit. The research and development managed expenditure related to ViiV Healthcare (previously reported within the Pharmaceuticals segment) and Vaccines (previously reported within the Vaccines segment) will be reported as part of the Research and Development segment. The Commercial Operations segment will also include the Group's global health initiatives that were previously separately reported through the Pharmaceuticals R&D and Vaccines segments as well as within Corporate and other unallocated costs;\n \n \n · \n The Research and Development segment includes the costs previously reported under the Pharmaceuticals R&D segment. The segment will also include...